In a pregnant patient with hypothyroidism, how should the thyroxine dose be managed?

In a pregnant patient with hypothyroidism, how should the thyroxine dose be managed?

• A. Increase the dose during pregnancy to maintain normal TSH and free T4.
• B. Keep the dose unchanged.
• C. Stop thyroxine during pregnancy.
• D. Adjust the dose as needed based on TSH and free T4 measurements and clinical status during pregnancy.

Answer: (D)

The important idea is that thyroid hormone needs often rise during pregnancy, so thyroid replacement must be adjusted rather than kept fixed. Pregnancy brings higher thyroid hormone requirements because estrogen increases thyroid-binding globulin, there’s greater volume of distribution, and placental deiodinase activity changes hormone metabolism. Early in pregnancy, hCG can modestly affect TSH, so the most reliable way to ensure the mother and fetus stay euthyroid is to tailor the levothyroxine dose based on serial TSH and free T4 measurements and the patient’s clinical status. Thus, the best approach is to adjust the dose as needed based on these labs and symptoms during pregnancy. Stopping therapy, keeping the dose unchanged, or making a fixed increase for all patients won’t reliably maintain euthyroidism and can risk adverse outcomes for mother and fetus.

The important idea is that thyroid hormone needs often rise during pregnancy, so thyroid replacement must be adjusted rather than kept fixed. Pregnancy brings higher thyroid hormone requirements because estrogen increases thyroid-binding globulin, there’s greater volume of distribution, and placental deiodinase activity changes hormone metabolism. Early in pregnancy, hCG can modestly affect TSH, so the most reliable way to ensure the mother and fetus stay euthyroid is to tailor the levothyroxine dose based on serial TSH and free T4 measurements and the patient’s clinical status.

Thus, the best approach is to adjust the dose as needed based on these labs and symptoms during pregnancy. Stopping therapy, keeping the dose unchanged, or making a fixed increase for all patients won’t reliably maintain euthyroidism and can risk adverse outcomes for mother and fetus.